Navigation Links
Jefferson researchers mirror human response to bacterial infection and resolution in mice
Date:12/14/2011

PHILADELPHIAImitating human diseases using an animal model is a difficult task, but Thomas Jefferson University researchers have managed to come very close.

Reporting in the Proceedings of the National Academy of Sciences, a team of Jefferson immunologists found that a specialized "human immune system" mouse model closely mimics a person's specific response and resolution of a tick-borne infection known as relapsing fever, caused by the bacteria Borrelia hermsii.

The response is so strikingly similar that it gives good reason for researchers to apply the strategy to a host of other infections to better understand how the immune system attempts to fights them which could ultimately lead to precise treatment and prevention strategies.

"This is first time an interaction of an infectious agent with a host, the progression of the disease and its eventual resolution recapitulates what you would see in a human being," said Kishore R. Alugupalli, Ph.D., Assistant Professor of Microbiology and Immunology at Thomas Jefferson University and the Kimmel Cancer Center at Jefferson. "Our model is not only a susceptible model, but it actually tells us how the human immune system is functionally working. That is the big difference from the previous studies."

What really surprised the team is that the mouse physiological environment was able to facilitate the development of human B1-like cells, which is specialized type of antibody producing systems used to fight infection due to a variety of bacterial pathogens, including Pneumococcus and Salmonella.

In the study, researchers transferred hematopoietic stem cells from human umbilical cord blood into mice lacking their own immune system. This resulted in development of a human immune system in these mice. These "human immune system" (HIS) mice were then infected to gauge response.

According to the authors, an analysis of spleens and lymph nodes revealed that the mice developed a population of B1b-like cells that may have fought off the infection. Researchers also observed that reduction of those B cells resulted in recurrent episodes of bacteremia, the hallmark of relapsing fever.

"The B1b cells in humans had been speculated, but never confirmed," said co-author Timothy L. Manser, Ph.D., Professor and Chair of the Department of Microbiology and Immunology at Jefferson. "We found that in mice, the B1b cell subset is critically important for resolution of this type of bacterial infection."

"This would indicate that there is a functional equivalent of the subset in humans that has not been previously recognized," he added.

The mouse model with relapsing fever recapitulates many of the clinical manifestations of the disease and has previously revealed that T cell-independent antibody responses are required to resolve the bacteria episodes. However, it was not clear whether such protective humoral responses are mounted in humans.

"It's an amazing platform that could be used to really study how the human B1 cells could work against a variety of bacterial and viral infections," said Dr. Alugupalli.


'/>"/>

Contact: Steve Graff
stephen.graff@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Thomas Jefferson University receives Science Centers QED Award for pancreatic cancer research
2. Jefferson researchers study outcomes of carotid artery stenting following prior carotid procedure
3. Jefferson is first academic medical center to offer FDA-approved BRAF mutation for melanoma patients
4. Thomas Jefferson University Hospital cuts Whipple procedure wound infections in half with new measures
5. Jefferson physician named an Educator of the Year by the Assocociation of Residents in Radiation Oncology
6. Thomas Jefferson University Hospital adopts new imaging agent to improve detection of bladder cancer
7. Thomas Jefferson University and hospitals tasked to find new radiation drugs
8. FDA approval of brain aneurysm device gives Jefferson neurosurgeons another life-saving tool
9. Jefferson doctors strengthen case for high-dose radiotherapy technique after radical prostatectomy
10. Kimmel Cancer Center at Jefferson breast cancer symposium features latest in research, treatment
11. Jefferson clinical trial: Can a cholesterol drug prevent colon cancer?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
(Date:10/12/2017)... ANGELES (PRWEB) , ... October 12, 2017 , ... ... Parsa Mohebi Hair Restoration, has recently contributed a medical article to the newly ... on cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... one of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. ... awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 ... ... Company, Cal Dining at the University of California Berkeley, and other leading institutions ... leverages the buying power of institutions to change the way animals are raised ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... today announced that its MyDario product is expected to appear on The ... when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz ... The ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
Breaking Medicine Technology: